The United States (US) Advisory Committee on Immunization Practices recommends a 2-dose series of HAV or a 3-dose series of HAV+HBV vaccinations for all patients with CLD, including those with HBV, HCV, cirrhosis, NAFLD, alcoholic liver disease, autoimmune hepatitis, or alanine aminotransferase or aspartate aminotransferase level >2 the upper limit of normal.20 Similarly, in the United Kingdom (UK), patients with various chronic liver conditions are recommended to receive HAV vaccination.21 This evidence concerns the gene GPT and congenital secretory chloride diarrhea 1.